Cervical cancer radiotherapy leaves important ureteral, urethral and vaginal toxicities under-monitored

A narrative review identifies clinically important late complications affecting less routinely contoured pelvic structures, with few validated dose constraints.

KEY POINTS

  • This narrative review examines less routinely monitored organs at risk during definitive chemoradiotherapy and image-guided brachytherapy for locally advanced cervical cancer. Beyond the standard bladder, rectum, sigmoid and bowel constraints, the authors focus on the ureters, urethra, vagina, lower-extremity lymphatic system and pelvic bones, reviewing reported toxicities, contouring approaches, dose relationships and long-term management.
  • Severe ureteral stricture is uncommon overall but strongly dependent on disease extent. In the EMBRACE-I cohort of 1,251 patients, the five-year actuarial risk of grade ≥3 ureteral stricture was 2.9%, increasing from 1.0% in stage II to 10.8% in stage III and 21.3% in stage IVA disease. Advanced T stage combined with baseline hydronephrosis emerged as an important predictor, emphasizing the difficulty of separating radiation injury from tumor-related urinary tract damage.
  • No universally accepted ureteral contouring standard or dose constraint exists. Small-volume measures such as D0.1cc may be useful for narrow tubular structures exposed to steep brachytherapy gradients; one retrospective analysis reported grade ≥3 stenosis in 28.6% of ureters receiving D0.1cc ≥77 Gy versus 7.5% below this level, while other cohorts found no significant association. The 77-Gy level is exploratory, not a validated planning threshold.
  • Urethral toxicity remains incompletely characterized because urinary frequency, dysuria, incontinence and cystitis are often reported together rather than attributed to individual lower urinary tract structures. Proposed urethral metrics include D0.1cc, D2cc, D50%, and anatomical landmarks such as the internal urethral ostium and posterior-inferior border of the pubic symphysis; however, contouring endpoints and clinically predictive parameters vary between studies.
  • Vaginal late effects represent a substantial quality-of-life burden. EMBRACE-I reported a 5.7% five-year actuarial risk of grade ≥3 vaginal toxicity, including 4.0% vaginal stenosis, while other studies found grade ≥2 vaginal morbidity in approximately 20–28% of patients over two to five years. Patient-reported sexual dysfunction can be much more frequent than clinician-graded toxicity, supporting combined CTCAE and validated patient-reported outcome assessment.
  • The most consistent vaginal dose-response evidence involves rectovaginal reference-point and PIBS-based dose reporting. Historical EMBRACE data associated rectovaginal reference-point doses of 65, 75 and 85 Gy EQD2 with approximately 20%, 27% and 34% risks of grade ≥2 stenosis, respectively. Proposed planning objectives include PIBS dose below 50 Gy and limiting distal vaginal exposure where oncologically feasible, but no universal constraint is established for every vaginal substructure.
  • Additional under-recognized late effects include lower-limb lymphedema and pelvic insufficiency fractures. EMBRACE reported five-year grade ≥2 lower-limb edema in approximately 6.6% and grade ≥3 edema in 0.5%, while a meta-analysis of 3,633 cervical cancer patients estimated pelvic insufficiency fracture prevalence at 14%, increasing to 17% in MRI-based studies. These events reflect multiple risk factors, including baseline health, surgery, bone quality and irradiation, limiting attribution to specific dose metrics.

CLINICAL TAKEAWAY

Cervical cancer radiotherapy toxicity assessment should extend beyond the bladder and gastrointestinal structures, particularly when advanced disease or brachytherapy geometry exposes the ureters, urethra, vagina and pelvic support tissues. This review supports greater attention to organ-specific contouring, dose reporting and long-term symptom assessment, but most proposed constraints remain investigational and should not compromise established target coverage.

SOURCE

Radiation Oncology

Browse more research Suggest a correction